New data shows physicians alter extended endocrine therapy for over 40% of breast cancer patients after Breast Cancer Index testing

New data reveals that Breast Cancer Index (BCI) testing significantly influences physicians’ recommendations regarding extended endocrine therapy for breast cancer patients. Following BCI testing, over 40% of patients experienced a change in their treatment plan, indicating the test’s pivotal role in personalized cancer care. The Breast Cancer Index provides critical insights into the risk of cancer recurrence, allowing clinicians to tailor extended endocrine therapy decisions more effectively. This shift in clinical practice underscores the growing importance of genomic testing in optimizing treatment duration beyond the standard five years. By identifying patients who truly benefit from prolonged therapy, BCI testing helps minimize unnecessary side effects and improves quality of life. These findings highlight a major advancement in the management of hormone receptor-positive breast cancer, promoting a precision medicine approach. As a result, the integration of BCI testing into routine oncology practice is gaining momentum in improving patient outcomes.

Business Wire